关键信息
-
基因名
CD47
- 应用
-
别名
CD47；MER6；Leukocyte surface antigen CD47
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q08722-3
-
表达区间
19-139aa
-
氨基酸序列
QLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTF DGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTE LTREGETIIELKYRVVSWFSP
-
分子量
40 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
CD47, also known as the "don't eat me" signal, is a cell surface protein that plays a crucial role in regulating the immune response by inhibiting phagocytosis, the process by which immune cells engulf and destroy pathogens or damaged cells. Its interaction with the immune inhibitory receptor SIRPα on macrophages sends a signal that prevents these immune cells from attacking healthy tissues. Overexpression of CD47 is commonly observed in various types of cancer, allowing cancer cells to evade immune surveillance. Consequently, research focused on CD47 and its pathways has gained significant attention, particularly in the context of cancer immunotherapy. The development of CD47 recombinant proteins aims to elucidate its biological functions and identify potential therapeutic applications. These proteins can serve as tools to study CD47 interactions, influence cell signaling, and develop strategies to block this pathway, potentially enabling enhanced phagocytosis of cancer cells. Understanding the mechanisms underlying CD47's role in immune evasion can lead to innovative treatments that enhance the body’s ability to fight cancer by removing the protective signals that allow tumors to escape immune detection.
